

# The effect of the natural mineral supplement Aquamin™ together with the short chain fructooligosaccharide Nutraflora® on bone health in post-menopausal women

<b>Submission date</b> 12/08/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 02/10/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 01/08/2022	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Emeir Duffy

### Contact details

University of Ulster  
Coleraine Campus  
Coleraine  
United Kingdom  
BT52 1SA  
+44 (0)28 7032 3543  
em.duffy@ulster.ac.uk

## Additional identifiers

### Protocol serial number

N/A

## Study information

**Scientific Title**

The effect of the mineral supplement Aquamin™ together with the short chain fructooligosaccharide Nutraflora® on bone mineral density and bone turnover markers in post-menopausal women: a double-blind, randomised, placebo-controlled trial

**Study objectives**

Osteoporosis and low bone mass is becoming a major public health problem with post-menopausal women being at the highest risk. Osteoporosis is a disease characterised by low bone mineral density (BMD), where the structure of bone deteriorates, making it more susceptible to fractures, especially in the spine, hip and wrist. A recent animal study has shown the mineral supplement Aquamin™ to enhance bone mineral density. Furthermore, there is also evidence that short-chain fructooligosaccharide (Nutraflora®) supplementation enhances bone mineral density in rats. This study sets out to investigate the effect of supplementation of Aquamin™ together with the short chain fructooligosaccharide Nutraflora® on bone health using bone mineral density and bone turnover markers as indicators of bone health in post-menopausal women.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Research Ethics Committee of the University of Ulster approved on the 21st July 2008 (ref: REC /08/0083)

**Study design**

Double-blind randomised placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Osteoporosis

**Interventions**

Each treatment is incorporated into chocolate chews and will be supplemented with 2 x chocolate flavoured chews. Individuals are supplemented per day for 2 years.

Treatment 1: Placebo (maltodextrin)

Treatment 2: Aquamin™ (1800 mg/d) alone

Treatment 3: Aquamin™ (1800 mg/d) with Nutraflora® (3.6 g/d)

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Aquamin™, Nutraflora®

## **Primary outcome(s)**

Bone mineral density: dual energy X-ray absorptiometry

## **Key secondary outcome(s)**

1. Bone resorption and formation markers:
  - 1.1. Serum CTx: ELISA
  - 1.2. Urinary deoxypyridinoline cross-links: ELISA
  - 1.3. Urinary CTx: ELISA
2. Serum intact osteocalcin: ELISA
3. Serum N-terminal midfragment OC: ELISA
4. Vitamin D: ELISA
5. Free calcium: ELISA
6. Parathyroid hormone: ELISA
7. Salivary Cortisol: ELISA
8. Calcium: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
9. Phosphate: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
10. Full Blood Profile: Sysmex full blood analyser
11. Electrolytes: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
12. Liver function:
  - 12.1. Albumin: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, United)
  - 12.2. Alanine transaminase: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
  - 12.3. Gamma-glutamyltransferase: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, United)
  - 12.4. Total bilirubin: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, United)
  - 12.5. Alkaline Phosphatase: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
13. Total protein: Automated instrument (Instrumentation Laboratories UK Ltd, Warrington, UK)
14. Anthropometric measurements: height, weight, waist circumference, measured using standardised procedures
15. Blood pressure
16. Mean daily dietary intake (4-day diet diary)
17. Habitual dietary intake: Food Frequency Questionnaire
18. Exercise: Physical Activity Questionnaire
19. Sun Exposure: Questionnaire

## **Completion date**

31/07/2011

## **Eligibility**

### **Key inclusion criteria**

1. Apparently healthy post-menopausal female volunteers (defined as having no menstrual period, bleeding or spotting during 1 year prior to enrolment)
2. Aged 48 - 75 years old
3. Weight less than 136 kg (DEXA [dual energy x-ray absorptiometry] limit 136 kg)
4. Community dwelling and fully mobile, with hormone implants (if used) removed at least one year prior to randomisation

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Female

**Total final enrolment**

300

**Key exclusion criteria**

1. Osteoporotic bone density (T-score less than -2.5)
2. Corticosteroid medications during the previous 6 months
3. History/presence of chronic renal, hepatic, gastrointestinal disease or traumatic lumbar compression fracture
4. Evidence of collapsed or focal vertebral sclerosis
5. Menopause before the age of 40 years
6. Bone diseases or other condition known to affect bone status
7. Treatment with specific therapy for osteoporosis
8. Uncontrolled hypertension or heart failure, renal calculi
9. Volunteers should not have used any prescribed medication known to affect bone status
10. Use of dietary supplements containing calcium and vitamin D three months prior to the study

**Date of first enrolment**

01/01/2009

**Date of final enrolment**

31/07/2011

**Locations****Countries of recruitment**

United Kingdom

Northern Ireland

Ireland

**Study participating centre**

University of Ulster

Coleraine

United Kingdom

BT52 1SA

# Sponsor information

**Organisation**

Marigot Ltd (Ireland)

**ROR**

<https://ror.org/05kmpn815>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Marigot Ltd (Ireland)

## Results and Publications

**Individual participant data (IPD) sharing plan**

Not provided at time of registration

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/03/2014		Yes	No
<a href="#">Other publications</a>	Associations of long chain polyunsaturated fatty acids with bone mineral density and bone turnover	30/07/2022	01/08/2022	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes